Last10K.com

Anixa Biosciences Inc (ANIX) SEC Filing 10-K Annual report for the fiscal year ending Thursday, October 31, 2019

Anixa Biosciences Inc

CIK: 715446 Ticker: ANIX
Document And Entity Information - USD ($)
12 Months Ended
Oct. 31, 2019
Jan. 08, 2020
Apr. 30, 2019
Document Information Line Items   
Entity Registrant NameAnixa Biosciences Inc  
Document Type10-K  
Current Fiscal Year End Date--10-31  
Entity Common Stock, Shares Outstanding 20,821,204 
Entity Public Float  $ 72,311,537
Amendment Flagfalse  
Entity Central Index Key0000715446  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Filer CategoryNon-accelerated Filer  
Entity Well-known Seasoned IssuerNo  
Document Period End DateOct. 31, 2019  
Document Fiscal Year Focus2019  
Document Fiscal Period FocusFY  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
Entity Shell Companyfalse  
Entity Ex Transition Periodfalse  
Entity Interactive Data CurrentYes  

View differences made from one year to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Revenue
Financial
Other
Filter by Subcategory:
All
Product
Expense
Cash Flow
Shares
Other
Inside Anixa Biosciences Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parentheticals)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Equity
Consolidated Statements Of Operations
Consolidated Statements Of Operations (Parentheticals)
Accounting Policies, By Policy (Policies)
Accrued Expenses
Accrued Expenses (Details) - Accrued Liabilities
Accrued Expenses (Tables)
Business And Funding
Business And Funding (Details)
Commitments And Contingencies
Commitments And Contingencies (Details)
Income Taxes
Income Taxes (Details)
Income Taxes (Details) - Income Tax Provision (Benefit)
Income Taxes (Details) - Reconciliation Of Income Taxes At The Federal Statutory Tax Rate
Income Taxes (Details) - The Tax Effects Of Temporary Differences Of The Deferred Tax
Income Taxes (Tables)
Segment Information
Segment Information (Details)
Segment Information (Details) - Segments Information
Segment Information (Tables)
Shareholders' Equity
Shareholders' Equity (Details) - Common Stock Purchase Warrants
Shareholders' Equity (Details) - Employee Stock Purchase Plan
Shareholders' Equity (Details) - Information Regarding Stock Options Outstanding That Were Not Granted Under The 2003 Share Plan, The 2010 Share Plan Or The 2018 Share Plan
Shareholders' Equity (Details) - Information Regarding The 2003 Share Plan
Shareholders' Equity (Details) - Information Regarding The 2010 Share Plan
Shareholders' Equity (Details) - Information Regarding The 2018 Share Plan
Shareholders' Equity (Details) - Re-Priced Stock Options
Shareholders' Equity (Details) - Stock Option Plans
Shareholders' Equity (Details) - Stock Options Outstanding And Exercisable That Were Not Granted Under The 2003 Share Plan, The 2010 Share Plan Or The 2018 Plan
Shareholders' Equity (Details) - Stock Options Outstanding And Exercisable Under The 2003 Share Plan
Shareholders' Equity (Details) - Stock Options Outstanding And Exercisable Under The 2010 Share Plan
Shareholders' Equity (Details) - Stock Options Outstanding And Exercisable Under The 2018 Share Plan
Shareholders' Equity (Tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Details) - Changes In Noncontrolling Interest
Summary Of Significant Accounting Policies (Details) - Hierarchy For Our Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis
Summary Of Significant Accounting Policies (Details) - Weighted Average Assumptions Used In Estimating The Fair Value Of Stock Options
Summary Of Significant Accounting Policies (Tables)
Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001513162-20-000009
Submitted to the SEC: Thu Jan 09 2020 4:16:35 PM EST
Accepted by the SEC: Thu Jan 09 2020
Period: Thursday, October 31, 2019
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001513162-20-000009.htm